Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) reached a new 52-week high during trading on Thursday . The company traded as high as C$0.10 and last traded at C$0.10, with a volume of 20000 shares traded. The stock had previously closed at C$0.10.
Hemostemix Stock Up 11.1 %
The company’s fifty day simple moving average is C$0.08 and its 200 day simple moving average is C$0.06. The stock has a market capitalization of C$8.71 million, a price-to-earnings ratio of -5.00 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Quiet Period Expirations Explained
- Battle of the Retailers: Who Comes Out on Top?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- What is the Euro STOXX 50 Index?
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
